

<u>Trademark</u>	<u>Chemical Name</u>
Warner-Lambert CI-986	5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt
Warner-Lambert CI-987	5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2,4-thiazolidinedione
Wellcome BW-B218C	N-hydroxy-N-[1-methyl-3-(3-phenoxyphenyl)-2-propenyl]-acetamide
Yoshitomi Y-19432	1-butyl-5-hydroxy-2-methyl-N-[1-(2-phenylethyl)-4-piperidiny]-1H-indole-3-carboxamide, hydrochloride
Zeneca ZM 230487	(6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy)methyl]-1-ethyl-2-quinolone
Zeneca ZD-2138	6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone
Zeneca ICI-211965	1-[3-(naphth-2-ylmethoxy)phenyl]-1-(thiazol-2-yl)propyl methyl ether
Zeneca ZM-216800	2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1H-inden-1-yl]-thiazole
zileuton	N-(1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea

Replace the paragraph beginning at page 11, line <sup>31</sup>35, with the following:

RP 7/25/06

Compositions of the invention would also be useful in adjunct therapy involving, typically, coadministration with an additional immunosuppressive agent, such as a cyclosporin compound, or Fujisawa FK-506, or rapamycin, or a glucocorticoid, or an antiproliferative agent, or a monoclonal antibody such as an anti-CD3 (anti-T cell receptor antibody) or anti-CD5/CD7 or anti-CD4 agent, or an anti-IL-2 receptor (anti-cytokine receptor antibody) agent or an anti-IL-2 (anti-cytokine antibody), or Nippon NKT-01 (15-deoxyspergualin) or Syntex RS-61443.